Loading stock data…
$5.67-0.11 (-1.82%)
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Kyverna Therapeutics, Inc. in the Healthcare sector is trading at $5.70 with a market capitalization of $428M. Wall Street consensus targets $30.40 (5 analysts), implying a +433.3% move over the next 12 months. The stock is currently near its 52-week low of $5.61, remaining 31.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$39.56M↑ | -$41.37M↓ | -$39.28M↓ | -$38.73M↑ | -$44.41M |
| Net Income | -$38.32M↑ | -$39.73M↓ | -$37.80M↓ | -$36.79M↑ | -$42.08M |
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment o...